Cara Therapeutics Inc
NASDAQ:CARA

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:CARA
Watchlist
Price: 18.2486 USD 243.02% Market Closed
Market Cap: 83.4m USD

Operating Margin

-740.1%
Current
Declining
by 152.3%
vs 3-y average of -587.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-740.1%
=
Operating Income
$-52.8m
/
Revenue
$7.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-740.1%
=
Operating Income
$-52.8m
/
Revenue
$7.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Cara Therapeutics Inc
NASDAQ:CARA
83.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.1B USD
Loading...

Market Distribution

Lower than 92% of companies in the United States of America
Percentile
8th
Based on 14 112 companies
8th percentile
-740.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Cara Therapeutics Inc
Glance View

Market Cap
83.4m USD
Industry
Pharmaceuticals

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

CARA Intrinsic Value
13.8455 USD
Overvaluation 24%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-740.1%
=
Operating Income
$-52.8m
/
Revenue
$7.1m
What is Cara Therapeutics Inc's current Operating Margin?

The current Operating Margin for Cara Therapeutics Inc is -740.1%, which is below its 3-year median of -587.8%.

How has Operating Margin changed over time?

Over the last 3 years, Cara Therapeutics Inc’s Operating Margin has decreased from -387.4% to -740.1%. During this period, it reached a low of -938.3% on Jun 30, 2024 and a high of -137% on Jun 30, 2022.

Back to Top